SHARE-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Weighted Average Grant Date Fair Value

WEIGHTED AVERAGE GRANT DATE FAIR VALUE	2023		2022		2021
Stock options	$	36.10	$	34.03	$	40.64
RSUs	89.60		87.68		104.98
PSUs/Performance shares	89.44		95.40		108.51

Stock-Based Compensation Activity

STOCK-BASED COMPENSATION ACTIVITY	Stock options						RSUs
	Shares (in thousands)	Weighted average exercise price		Weighted average contractual term (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding at January 1, 2023	31,023	$	142.68				9,687	$	79.82
Spin-off adjustment(a)	3,704	N/A					(784)	N/A
Granted	358	88.15					3,203	89.60
Exercised	(7,275)	77.64					(3,480)	67.96
Forfeited	(21)	64.46					(523)	69.73
Expired	(5,216)	152.04					N/A	N/A
Outstanding at December 31, 2023	22,573	$	122.35	3.0	$	544	8,103	$	76.52	1.1	$	1,034
Exercisable at December 31, 2023	21,389	$	124.83	2.8	$	484	N/A	N/A		N/A	N/A
Expected to vest	1,098	$	77.50	7.7	$	55	7,313	$	76.09	1.0	$	933

(a) The spin-off adjustment represents the net of shares converted into new GE awards and shares converted and transferred to GE HealthCare Technologies Inc. as a result of the January 3, 2023 separation of GE HealthCare.

Schedule of Compensation Expense

	2023		2022		2021
Compensation expense (after-tax)(a)	$	299	$	251	$	305
Cash received from stock options exercised	565		62		93
Intrinsic value of stock options exercised and RSU/PSUs vested	561		170		217

(a) Unrecognized compensation cost related to unvested equity awards as of December 31, 2023 was $318 million, which will be amortized over a weighted average period of 1.0 year. Income tax benefit recognized in earnings was $61 million, $12 million and an insignificant amount in 2023, 2022, and 2021, respectively.

Schedule of Cash Proceeds and Intrinsic Value

	2023		2022		2021
Compensation expense (after-tax)(a)	$	299	$	251	$	305
Cash received from stock options exercised	565		62		93
Intrinsic value of stock options exercised and RSU/PSUs vested	561		170		217

(a) Unrecognized compensation cost related to unvested equity awards as of December 31, 2023 was $318 million, which will be amortized over a weighted average period of 1.0 year. Income tax benefit recognized in earnings was $61 million, $12 million and an insignificant amount in 2023, 2022, and 2021, respectively.